Newsletter Signup | Join Community
The US Food and Drug Administration approves Keytruda for treatment of advanced SCLC.
Study suggests that first line chemotherapy + Iressa is a new standard treatment option for EGFR + NSCLC
Studies demonstrate the effectiveness of Tagrisso® as initial and advanced treatment of EGFR + NSCLC
Could Neoadjuvant Immunotherapy be The Next Major Treatment Advance for Early Stage Non-Small Cell Lung Cancer?
Keytruda immunotherapy has become a standard of care for PD-1 + NSCLC: 5 Year survival data updated at ASCO 2019
TAPUR study suggests CDKN2A + lung cancer can be targeted with breast cancer drug Ibrance
Lung Cancer: Still Number One
Lobrena - a third generation ALK inhibitor drug with excellent CNS activity
Surgery, radiation, and systemic chemotherapy - precision cancer medicines are all used to treat stage IIIA NSCLC
Gilotrif as a single agent or in combination improves survival in EGFR + NSCLC.
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
I have small cell lung cancer; radiation to prevent spread to the brain has been recommended but…
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…